<DOC>
	<DOCNO>NCT01086410</DOCNO>
	<brief_summary>The purpose study assess effect six week ' treatment two once-daily strength Fluticasone Furoate/GW642444 Inhalation Powder HPA axis system</brief_summary>
	<brief_title>Safety Study Effects Inhaled Fluticasone Furoate/GW642444 Hypothalamic-Pituitary-Adrenal ( HPA ) Axis</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Outpatient ability comply study requirement complete two 24hour clinic visit Clinical diagnosis asthma great than/equal 12 week Reversibility FEV1 least twelve percent two hundred milliliter FEV1 great equal fifty percent predict History life threaten asthma Respiratory infection oral candidiasis Asthma exacerbation Uncontrolled disease clinical abnormality Allergies study drug , study drug ' excipients , medication relate study drug Taking another investigational medication prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HPA axis</keyword>
</DOC>